Invivyd Q3 net loss $45.1M; cash $419M; NVD200 on track for Q1 2023 trial

Invivyd, Inc.

2022-Q3 EPS reported -$1.82

Net loss of $45.1M ($0.42 per share) vs $60.4M ($0.98) in Q3 2021; R&D expenses fell to $34.1M from $49.4M.
Cash, cash equivalents and marketable securities of $419M as of Sept 30, 2022; expected runway into Q2 2024.
NVD200 combination antibody candidate progressing toward clinical trial start in Q1 2023; demonstrated potent in vitro neutralization against Omicron sublineages.
David Hering named permanent CEO in July; Fred Driscoll appointed interim CFO and Christine Lindenboom to board in October.
Entered Platform Transfer Agreement with Adimab and signed 9,600 sq ft lease in Newton, MA for expanded lab space.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Invivyd, Inc. reported the third quarter ended September 30, 2022 results: net income $45.1 million, EPS $0.42 per share.

Period: the third quarter ended September 30, 2022
Net income: $45.1 million
EPS: $0.42 per share
Result: reported results

Exact text from the filing

Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-282613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.